Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study
|ClinicalTrials.gov Identifier: NCT00986635|
Recruitment Status : Completed
First Posted : September 30, 2009
Last Update Posted : April 8, 2011
|Condition or disease|
|Differences in Laboratory Coagulation Parameters|
To validate the effects of Rivaroxaban on coagulation parameters plasma samples of patients after hip or knee replacement surgery treated with Rivaroxaban 10 mg/d are investigated.
Plasma samples are obtained by blood collection before, after 2 hours and after 12 hours after Rivaroxaban dosing in steady state (on 3rd - 5th day).
Several techniques, including clot-based tests, chromogenic assays and ELISA´s are used for coagulation assays in our coagulation laboratory Frankfurt/Main. The influence of Rivaroxaban on different coagulation assays should be investigated in our coagulation laboratory.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Study Start Date :||September 2009|
|Actual Primary Completion Date :||June 2010|
|Actual Study Completion Date :||April 2011|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00986635
|University Hospital Frankfurt|
|Frankfurt am Main, Germany, 60590|
|Principal Investigator:||Helen Mani, PhD||Johann Wolfgang Goethe University Hospital Frankfurt/Main Germany|